Compare Cassava Sciences Inc (FLNA) vs McCormick & Company, Incorporated (MKC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs McCormick & Company, Incorporated — how do they compare? Cassava Sciences Inc trades at $1.07 (market cap $53.14M), while McCormick & Company, Incorporated trades at $52.28 (market cap $13.70B). The key difference: McCormick & Company, Incorporated is far larger — about 257.8× Cassava Sciences Inc's market cap, and McCormick & Company, Incorporated pays a 3.77% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| FLNA | MKC | |
|---|---|---|
Market Cap | $53.14M | $13.70B |
Sector | Health | Consumer Staples |
52-Week High | $4.64 | $72.81 |
52-Week Low | $1.09 | $45.60 |
Enterprise Value | -$33.43M | $18.30B |
Dividend Yield | — | 3.77% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $1.06, down 2.75% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows a low P/B of 0.78, yet profitability metrics are negative, including a -79.59% ROE and -$90.97M net income for 2025. Recent Q1 2026 earnings beat expectations, and analyst consensus is 66.7% buy. News highlights Q1 financial results and a scientific presentation on TSC-related epilepsy therapies.
Outlook remains speculative due to persistent losses and negative cash flows, offset by strong analyst support and recent earnings beats. Key risks include funding needs for drug development and competitive pressures, while potential upside hinges on clinical progress in TSC-related epilepsy treatments.
McCormick (MKC) trades at $52.85, down 1.67% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $59.67. The company reported strong Q2 2026 earnings of $0.80 per share, beating estimates, driven by acquisitions and margin expansion. Recent news highlights the transformative potential of the Unilever Foods deal, while financials show steady revenue growth and a net income margin of 21.91% for 2025.
The outlook is positive with 36.67% of analysts rating it a buy, citing undervaluation and strategic deals, but risks include soft consumer volumes and integration challenges. Upside hinges on execution of cost savings and volume recovery, with the current P/E of 8.47 suggesting value if growth accelerates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About McCormick & Company, Incorporated
In its 130-year history, McCormick has grown to become the leading global manufacturer, marketer, and distributor of spices, herbs, extracts, seasonings, and other flavorings. Beyond end consumers, McCormick's customer base also includes top quick-service restaurants, retail grocery chains, and other packaged food and beverage manufacturers, with about 30% of sales generated beyond its home turf to include 150 other countries and territories. In addition to its namesake brand, the firm's portfolio includes Old Bay, Zatarain's, Thai Kitchen, Frank's RedHot, French's, and the recently acquired Cholula brand.
Read more on MKC →
